Astellas Pharma terminated its collaboration with CytomX Therapeutics effective Q2 2026, choosing not to advance remaining preclinical programs despite positive early data124
The 2020 partnership provided CytomX $80 million upfront with potential for $1.6 billion in milestones and royalties for Probody-based bispecific antibodies in solid tumors12
CytomX's lead asset varsetatug masetecan (Varseta-M) showed 32% confirmed response rate, 7.1 months median PFS, and 84% disease control rate in Phase 1 metastatic CRC at 10 mg/kg dose14
CytomX maintains partnerships with Regeneron, Amgen, Bristol Myers Squibb, and Moderna, and reported $137.1 million cash lasting to Q2 2027234
Ongoing Varseta-M trials include Phase 1 with bevacizumab and planned Phase 1b/2 with bevacizumab plus chemotherapy by end of 202614
Sources:
1. https://www.biospace.com/business/astellas-divorces-cytomx-despite-positive-phase-1-data-for-antibody-platform
2. https://www.fiercebiotech.com/biotech/astellas-ends-16-billion-t-cell-engager-discovery-pact-cytomx
3. https://marketchameleon.com/articles/b/2026/3/16/cytomx-2025-results-strong-financial-position-pipeline-advances
4. https://natlawreview.com/press-releases/cytomx-therapeutics-announces-2025-financial-results-and-provides-business